Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence

Modern Pathology

Volumn 26, Issue 5, 2013, Pages 733-742

  Grupp, Katharina ^a   Kohl, Sebastian ^a   Sirma, Hüseyin ^a   Simon, Ronald ^a   Steurer, Stefan ^a   Becker, Andreas ^a   Adam, Meike ^a   Izbicki, Jakob ^a   Sauter, Guido ^a   Minner, Sarah ^a   Schlomm, Thorsten ^a   Tsourlakis, Maria Christina ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CHD1; CRISP3; ERG; FOXP1; MAP3K7; prostate cancer; PTEN

Indexed keywords

CYSTEINE RICH SECRETORY PROTEIN 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENT CANCER; TISSUE MICROARRAY;

ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SALIVARY PROTEINS AND PEPTIDES; SEMINAL PLASMA PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877050325     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.206     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Gibbs GM, Roelants K, O'Bryan MK. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, cancer, and immune defense. Endocr Rev 2008;29: 865-897.
3. Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-2180.
4. Kratzschmar J, Haendler B, Eberspaecher U, et al. The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur J Biochem 1996;236: 827-836.
5. Asmann YW, Kosari F, Wang K, et al. Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 2002;62:3308-3314.
6. Kosari F, Asmann YW, Cheville JC, et al. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11: 1419-1426.
7. Bjartell AS, Al-Ahmadie H, Serio AM, et al. Association of cysteine-rich secretory protein 3 and betamicroseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007;13:4130-4138.
8. Ribeiro FR, Paulo P, Costa VL, et al. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One 2011;6:e22317.
9. Bjartell A, Johansson R, Bjork T, et al. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006;66: 591-603.
10. Dahlman A, Edsjo A, Hallden C, et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis 2010;13:369-375.
11. Hoogland AM, Dahlman A, Vissers KJ, et al. Cysteinerich secretory protein 3 and beta-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome. BJU Int 2011;108:1356-1362.
12. Dahlman A, Rexhepaj E, Brennan DJ, et al. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis Mod Pathol 2011;24:708-719.
13. Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011;11:507.
14. Schlomm T, Heinzer H, Steuber T, et al. Full functional-length urethral sphincter preservation during radical prostatectomy. Eur Urol 2011;60:320-329.
15. Schlomm T, Tennstedt P, Huxhold C, et al. Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robotassisted laparoscopic radical prostatectomy: experience after 11 069 consecutive patients. Eur Urol 2012; 62:333-340.
16. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
17. Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-1560.
18. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-5888.
19. Kluth M, Hesse J, Heinl A, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2-ERG fusions. Mod Pathol 2012 (in press).
20. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of pten is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181:401-412.
21. Clauditz TS, Gontarewicz A, Lebok P, et al. Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. Oral Oncol 2012;48:991-996.
22. Muller J, Ehlers A, Burkhardt L, et al. Loss of p(Ser2448)-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer 2012; doi:10.1002/ijc.27768.
23. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011;71:281-288.
24. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-188.
25. Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelialto-mesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-6745.
26. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-6403.
27. Garde SV, Basrur VS, Li L, et al. Prostate secretory protein (PSP94) suppresses the growth of androgenindependent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38: 118-125.
28. Shukeir N, Arakelian A, Kadhim S, et al. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63: 2072-2078.
29. Pathak BR, Breed AA, Nakhawa VH, et al. Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific. Asian J Androl 2010;12: 677-689.
30. Chan PS, Chan LW, Xuan JW, et al. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999;41:99-109.
31. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
32. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2010;470:214-220.
33. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-8510.